

# The Most Cited Articles and Authors in JAAD in the Last Decade

Publications on psoriasis and skin cancer are among the most highly cited in the dermatology literature. Women authors remain underrepresented.

BY AMYLEE MARTIN, BS; AKSHITHA THATIPARTHI, BS; JEFFREY LIU, BS; AND JASHIN J WU, MD

>>> The field of dermatology is rapidly evolving and relies heavily on cutting edge research to guide diagnostic, treatment, and management plans. The dynamic nature of this specialty requires a centralized source to disseminate emerging research to all dermatologists, regardless of practice setting. The *Journal of The American Academy of Dermatology (JAAD)*, the official journal of the largest and most influential dermatological association, has served as a major distributor for disseminating research for several years.<sup>1,2</sup> Understanding the characteristics of the most cited JAAD articles will provide insight regarding the future direction for dermatology research. Despite the JAAD's current standing, a bibliometric analysis of the 50 most cited dermatology articles from 1974 to 2019 only included five JAAD articles.<sup>3</sup> However, it should be noted that JAAD was not established until 1979.<sup>4</sup> Consequently, we aimed to identify and analyze the characteristics of the top 50 most cited articles and authors in JAAD over the last decade and to compare our results to the bibliometric analysis by Maymone et al.<sup>3</sup>

## MATERIALS AND METHODS

We utilized the Web of Science (WOS), a leading citation index that includes more than 21,000 peer-reviewed journals, to determine the top 50 most cited articles and authors in JAAD over the last decade.<sup>5</sup> Specifically, we queried WOS Core Collection to retrieve JAAD publications using the dermatology category field tag. We filtered for JAAD documents published from January 2010 to September 2020. No other filters were applied. We selected the top 50 articles with the most citations for analysis.

Using title and abstract, we classified each publication as pathophysiology, epidemiology, prevention, clinical classification/staging system/diagnostic technique, or treatment/management.

In addition, our search provided a list of 100 authors with the highest number of JAAD publications over the last decade. From this list, we selected the 50 most cited authors by conducting WOS basic searches of the author category to obtain JAAD author citation reports for the last 10 years. Author's gender was determined from a Google search of the author's name with institutional affiliation. Data were extracted from September 24, 2020 to October 1, 2020.

## RESULTS

Our search yielded 15,774 documents for January 2010 to September 2020. The data were comprised of 58.7 percent meeting abstracts (N=9262), 15.4 percent letters (N=2423), 15.0 percent articles (N=2368), 7.6 percent editorial materials (N=1206), 2.7 percent reviews (N=424), and 1.19 percent "other" (N=188). The United States had the highest number of JAAD publications (59.02 percent, N=9310), followed by Spain (7.16 percent, N=1130) and Canada (5.86 percent, N=924).

The top 50 cited articles and authors are listed in Table I and II, respectively. Psoriasis (N=15) was the most frequently discussed disease followed by skin cancer and its associated risk factors (N=12). The 15 psoriasis articles were comprised of nine original articles, one continuing medical education article, three reviews, and two guidelines of care. These 15 psoriasis articles addressed epide-

miology (n=6), pathophysiology (n=1), and treatment/management (n=8). As far as top-cited skin cancer articles, there were four original articles, four continuing medical education articles, two reviews, and two guidelines of care. These 12 skin cancer articles focused on epidemiology (n=3), classification system/staging system/diagnostic technique (n=3), treatment/management (n=2), and prevention (n=4).

With regard to publication types for the 50 most cited articles, original articles (n=20) were the most common followed by continuing medical education (n=10), reviews (n=10), guidelines of care (n=9), and special reports (n=1). Of these 50 most cited articles, women comprised 36 percent (n=18) of first authors and 48 percent (n=24) of corresponding authors. For the 50 most cited JAAD authors, 28 percent (n=14) were women.

## DISCUSSION

In our analysis of the 50 most cited JAAD articles from the last decade, psoriasis (N=15, 30 percent) was the most represented disease; however, the number of skin cancer related articles (N=12, 24 percent) trailed closely behind. Likewise, in the bibliometric analysis by Maymone et al., examining the 50 most cited dermatology articles from 1974 to 2019, psoriasis (N=13, 26 percent) and skin cancer (N=8, 16 percent) were also prevalent topics.<sup>3</sup>

Skin cancer and psoriasis are likely popular in dermatology literature, in part, due to their high disease prevalence. Psoriasis is estimated to affect two to three percent of the population, while non-melanoma skin cancer (NMSC) has been estimated to be the most prevalent skin cancer within the United States.<sup>6,7</sup> Moreover, Wilmer et al. reported NMSC and psoriasis to be the third and eighth most common diseases encountered by dermatologists, respectively.<sup>8</sup>

Apart from being a common, debilitating skin disease, psoriasis continues to hold a central role in dermatology research due to its systemic inflammatory nature, making it a treatment priority. Psoriasis is associated with a host of comorbidities that may increase morbidity and mortality such as cardiovascular disease, diabetes mellitus, obesity, and psoriatic arthritis.<sup>9</sup> Important discoveries about the pathophysiology and epidemiology of this complex and burdensome disease continue to be made.<sup>10</sup> This ongoing progress in psoriasis epidemiology research is yet another contributory factor toward its popularity in the dermatology literature.

Besides epidemiology research, psoriasis treatments have also continued to advance within the last 20 years, with the approval of the first biologic for treatment of psoriasis in 2003.<sup>11</sup> Thenceforth, several other biologics and non-biologics have been approved.<sup>11</sup> Compared to prior psoriasis

treatments, biologics are much more effective with a more favorable side effect profile.<sup>12</sup> However, biologics still exhibit shortcomings such as high cost, inconvenient administration route/dosing schedule, and uncertain risk of malignancy.<sup>12-14</sup> As such, psoriasis treatments continue to be a critical area of research, with scientists diligently pursuing improvements in biologics.

Similar to psoriasis, skin cancer is also problematic. Skin cancer may lead to disfigurement and pain.<sup>15</sup> Moreover, melanoma may metastasize and lead to death.<sup>16</sup> As such, skin cancer prevention is a top priority and a highly relevant area of research. Within the last 20 years, there have been improvements and increased understanding of non-invasive imaging techniques, such as dermoscopy and reflective confocal microscopy, and development of new molecular technologies, such as DecisionDx-Melanoma.<sup>17-19</sup>

Furthermore, significant strides in systemic skin cancer treatments have been made in the last decade. Since 2011, several new therapies gained FDA approval for the treatment of metastatic melanoma including BRAF and MEK inhibitors; anti-CTLA-4 and anti-PD-1 antibodies; and modified oncolytic herpes virus.<sup>20</sup> New systemic therapies have also emerged for NMSC with approval of cemiplumab and pembrolizumab for advanced cutaneous squamous cell cancer in 2018 and 2020, respectively.<sup>21,22</sup> Moreover, vismodegib and sonidegib were approved for advanced basal cell carcinoma in 2012 and 2015, respectively.<sup>23,24</sup> Consequently, skin cancer is a frequently cited topic due to its high disease prevalence, considerable burden to society, and continued research progress in prevention, diagnosis, and treatment.

Regarding types of publications, the bibliometric analysis by Maymone et al. (top cited dermatology articles and authors from 1974 to 2019) included only a single guideline of care.<sup>3</sup> This is in contrast to our analysis, which yielded nine (18 percent) guidelines of care. This increase is likely due to rapid advances in technology and molecular biology, allowing for production of a higher quantity of publications at an accelerated rate.<sup>25</sup> Academic and community dermatologists alike may lack sufficient time to properly examine and interpret the overwhelming amount of new research. Proper use of new research requires careful appraisal of study validity. As such, the dermatology community benefits from synthesis of new research by a panel of experts with the proper knowledge and skills. Consequently, guidelines of care publications will likely continue to increase in popularity, as the volume of new research continues to expand.

In the analysis by Maymone et al. (most cited dermatology articles from 1974 to 2019), women only represented 12 percent of first authors, whereas women represented

**TABLE 1: THE 50 MOST CITED ARTICLES IN JAAD OVER THE PAST 10 YEARS**

Rank	Times Cited <sup>a</sup>	Article Title <sup>b</sup>	Publication Type <sup>c</sup>	Publication Classification <sup>d</sup>	Year Published	First Author (Sex); Corresponding Author (Sex)	Disease/Topic
1	495	Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies	Guidelines of care	Treatment/management	2014	Eichenfield, LF (M); Begolka, WS (F)	Atopic dermatitis
2	447	Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification	Review	Clinical classification, staging system, or diagnostic technique	2014	Fine, JD (M); Fine, JD (M)	Inherited epidermolysis bullosa
3	400	Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis	Guidelines of care	Treatment/management	2014	Eichenfield, LF (M); Begolka, WS (F)	Atopic dermatitis
4	366	Guidelines of care for the management of acne vulgaris	Guidelines of care	Treatment/management	2016	Zaenglein, AL (F); Bhushan, R (F)	Acne vulgaris
5	365	Psoriasis prevalence among adults in the United States	Original article	Epidemiology	2014	Rachakonda, TD (F); Armstrong, AW (F)	Psoriasis
6	356	Guidelines of care for the management of atopic dermatitis: Section 3. Management and Treatment with Phototherapy and Systemic Agents	Guidelines of care	Treatment/management	2014	Sidbury, R (M); Begolka, WS (F)	Atopic dermatitis
7	354	Revised nomenclature and classification of inherited ichthyoses: Results of the First Ichthyosis Consensus Conference in Sorèze 2009	Special report	Clinical classification, staging system, or diagnostic technique	2010	Oji, V (M); Oji, V (M)	Inherited ichthyoses
8	332	Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012	Original article	Epidemiology	2013	Karia, PS (M); Schmults, CD (F)	Cutaneous squamous cell carcinoma
9	304	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions	Guidelines of care	Treatment/management	2011	Menter, A (M); Bhushan, R (F)	Psoriasis
10	301	Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system	Original article	Clinical classification, staging system, or diagnostic technique	2010	Lemos, BD (F); Nghiem, P (M)	Merkel cell carcinoma
11	297	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial	Original article	Treatment/management	2017	Blauvelt, A (M); Blauvelt, A (M)	Psoriasis
12	294	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial	Original article	Treatment/management	2015	Thaci, D (M); Thaci, D (M)	Psoriasis
13	262	Vitiligo: A comprehensive overview: Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up	Continuing medical education	Epidemiology/pathophysiology	2011	Alikhan, A (M); Petronic-Rosic, V (F)	Vitiligo
14	257	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial	Original article	Treatment/management	2017	Reich, K (M); Reich, K (M)	Psoriasis
15	250	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)	Original article	Treatment/management	2015	Papp, K (M); Papp, K (M)	Psoriasis

**TABLE I: THE 50 MOST CITED ARTICLES IN JAAD OVER THE PAST 10 YEARS (CONTINUED)**

Rank	Times Cited <sup>a</sup>	Article Title <sup>b</sup>	Publication Type <sup>c</sup>	Publication Classification <sup>d</sup>	Year Published	First Author (Sex); Corresponding Author (Sex)	Disease/Topic
16	248	The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study	Original article	Clinical classification, staging system, or diagnostic technique	2011	Fiorentino, D (M); Fiorentino, D (M)	Dermatomyositis
17	247	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey	Original article	Epidemiology	2014	Lebwohl, MG (M); Lebwohl, MG (M)	Psoriasis
18	247	Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006	Continuing medical education	Epidemiology	2011	Jemal, A (M); Jemal, A (M)	Melanoma
19	234	Alopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis	Continuing medical education	Pathophysiology	2010	Alkhalifah, A (M); Shapiro, J (M)	Alopecia Areata
20	232	Infliximab therapy for patients with moderate to severe hidradenitis, suppurativa: A randomized, double-blind, placebo-controlled crossover trial	Original article	Treatment/management	2010	Grant, A (F); Kerdel, FA (M)	Hidradenitis suppurativa
21	225	Guidelines of care for the management of primary cutaneous melanoma	Guidelines of care	Treatment/management	2011	Bichakjian, CK (M); Bhushan, R (F)	Melanoma
22	221	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy	Guidelines of care	Treatment/management	2010	Menter, A (M); Bhushan, R (F)	Psoriasis
23	215	Psoriasis and Comorbid Diseases: Epidemiology	Continuing medical education	Epidemiology	2017	Takeshita, J (F); Takeshita, J (F)	Psoriasis
24	208	Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults	Original article	Treatment/management	2016	Paller, AS (F); Paller, AS (F)	Atopic dermatitis
25	203	AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: A report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery	Guidelines of care	Treatment/management	2012	Connolly, SM (F); Begolka, WS (F)	Skin cancer
26	197	Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies	Review	Epidemiology	2013	Armstrong, AW (F); Armstrong, AW (F)	Psoriasis
27	194	Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics	Original article	Epidemiology	2013	Mease, PJ (M); Mease, PJ (M)	Psoriasis
28	189	Frontal fibrosing alopecia: A multicenter review of 355 patients	Original article	Epidemiology/treatment/management	2014	Vano-Galvan, S (M); Vano-Galvan, S (M)	Frontal fibrosing alopecia
29	189	Skin cancer in solid organ transplant recipients: Advances in therapy and management: Part I. Epidemiology of skin cancer in solid organ transplant recipients	Continuing medical education	Epidemiology	2011	Zwald, FO (F); Zwald, FO (F)	Skin cancer
30	189	Wound healing in the 21st century	Review	Pathophysiology	2010	Schreml, S (M); Schreml, S (M)	Wound healing
31	188	Dermatoscopy of basal cell carcinoma: Morphologic variability of global and local features and accuracy of diagnosis	Original article	Clinical classification, staging system, or diagnostic technique	2010	Altamura, D (M); Peris, K (F)	Basal cell carcinoma
32	178	Interleukin 17A: Toward a new understanding of psoriasis pathogenesis	Review	Pathophysiology	2014	Lynde, CW (M); Lynde, CW (M)	Psoriasis
33	178	Update on morphea: Part I. Epidemiology, clinical presentation, and pathogenesis	Continuing medical education	Epidemiology/pathophysiology	2011	Fett, N (F); Fett, N (F)	Morphea

**TABLE I: THE 50 MOST CITED ARTICLES IN JAAD OVER THE PAST 10 YEARS (CONTINUED)**

Rank	Times Cited <sup>a</sup>	Article Title <sup>b</sup>	Publication Type <sup>c</sup>	Publication Classification <sup>d</sup>	Year Published	First Author (Sex); Corresponding Author (Sex)	Disease/Topic
34	178	How to diagnose nonpigmented skin tumors: A review of vascular structures seen with dermoscopy-Part II. Nonmelanocytic skin tumors	Continuing medical education	Clinical classification, staging system, or diagnostic technique	2010	Zalaudek, I (F); Zalaudek, I (F)	Nonpigmented skin tumors
35	177	Prevalence of sunburn, sun protection, and indoor tanning behaviors among Americans: Review from national surveys and case studies of 3 states	Continuing medical education	Prevention	2011	Buller, DB (M); Buller, DB (M)	Sunburn/ photoprotection/ indoor tanning
36	169	Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa	Original article	Pathophysiology	2011	Schlapbach, C (M); Hunger, RE (M)	Hidradenitis suppurativa
37	162	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis	Original article	Treatment/management	2016	van de Kerkhof, PCM (M); van de Kerkhof, PCM (M)	Psoriasis
38	161	New insights into rosacea pathophysiology: A review of recent findings	Review	Pathophysiology	2013	Steinhoff, M (M); Steinhoff, M (M)	Rosacea
39	161	Systematic skin cancer screening in Northern Germany	Original article	Prevention	2012	Breitbart, EW (M); Breitbart, EW (M)	Skin cancer
40	161	Adverse reactions to injectable soft tissue fillers	Continuing medical education	Treatment/management	2011	Requena, L (M); Requena, L (M)	Soft tissue filler reactions
41	158	Sunscreens: An overview and update	Review	Prevention	2011	Sambandan, DR (F); Sambandan, DR (F)	Sunscreen
42	156	Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome	Original article	Clinical classification, staging system, or diagnostic technique	2012	Braun-Falco, M (M); Braun-Falco, M (M)	Pyoderma gangrenosum; acne; suppurative hidradenitis
43	154	Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches	Guidelines of care	Treatment/management	2014	Sidbury, R (M); Begolka, WS (F)	Atopic dermatitis
44	152	Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies	Original article	Treatment/management	2013	Elewski, BE (F); Elewski, BE (F)	Onychomycosis
45	152	The role of antioxidants in photoprotection: A critical review	Review	Prevention/ pathophysiology/	2012	Chen, L (F); Wang, SQ (M)	Photoprotection
46	151	Alopecia areata update: Part II. Treatment	Continuing medical education	Treatment/management	2010	Alkhalifah, A (M); Shapiro, J (M)	Alopecia areata
47	149	Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors	Review	Epidemiology	2013	Miller, IM (F); Miller, IM (F)	Psoriasis
48	145	Tele dermatology for diagnosis and management of skin conditions: A systematic review	Review	Treatment/management	2011	Warshaw, EM (F); Warshaw, EM (F)	Tele dermatology
49	142	Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts	Review	Clinical classification, staging system, or diagnostic technique	2012	Murrell, DF (F); Murrell, DF (F)	Bullous pemphigoid
50	142	The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials	Original article	Treatment/management	2011	Dommasch, ED (F); Gelfand, JM (M)	Psoriasis

<sup>a</sup>Times cited was based on data from WOS Core Collection

<sup>b</sup>Obtained from WOS Core Collection search using the dermatology category field tag after filtering for articles published by JAAD from January 2010 to September 2020

<sup>c</sup>Obtained from publisher provided descriptor of publication type at top of the full-length article; if none listed, publication type assigned using title and abstract

<sup>d</sup>Classified according to title and abstract

**TABLE II: THE TOP 50 MOST CITED AUTHORS IN JAAD OVER THE LAST 10 YEARS**

Rank	Name (Sex)	Times Cited: JAAD Publications <sup>b</sup>	Number of JAAD Publications <sup>b</sup>	Most Cited JAAD Publication <sup>b</sup>	Year Published	JAAD H-index <sup>b</sup>
1	Lebwohl M (M)	3183	171	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions	2011	34
2	Paller AS (F)	2840	53	Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies	2014	22
3	Feldman S (M)	2809	171	Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies	2014	20
4	Simpson EL (M)	2362	32	Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies	2014	16
5	Reich K (M)	1963	115	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial	2015	16
6	Papp K (M)	1919	144	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial	2017	22
7	Margolis DJ (M)	1878	34	Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies	2014	14
8	Gelfand JM (M)	1860	53	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions	2011	22
9	Gordon K (M)	1822	87	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions	2011	15
10	Armstrong A (F)	1746	111	Psoriasis prevalence among adults in the United States	2014	21
11	Kimball A (F)	1735	137	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial	2017	21
12	Leonardi C (M)	1722	89	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions	2011	18
13	Blauvelt A (M)	1694	97	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial	2017	17
14	Menter A (M)	1673	95	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions	2011	22
15	Van Voorhees AS (F)	1663	36	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions	2011	19
16	Gottlieb A (F)	1640	127	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions	2011	22
17	Lim HW (M)	1562	64	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions	2011	19
18	Argenziano G (M)	1360	54	Dermatoscopy of basal cell carcinoma: Morphologic variability of global and local features and accuracy of diagnosis	2010	17
19	Schwartz RA (M)	1217	32	DRESS syndrome Part I. Clinical perspectives	2013	22
20	Zalaudek I (F)	1150	36	Dermatoscopy of basal cell carcinoma: Morphologic variability of global and local features and accuracy of diagnosis	2010	14
21	Werth VP (F)	972	33	Update on morphea: Part I. Epidemiology, clinical presentation, and pathogenesis	2011	15
22	Koo J (M)	957	50	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions	2011	12

**TABLE II: THE TOP 50 MOST CITED AUTHORS IN JAAD OVER THE LAST 10 YEARS (CONTINUED)**

Rank <sup>a</sup>	Name (Sex)	Times Cited: JAAD Publications <sup>b</sup>	Number of JAAD Publications <sup>b</sup>	Most Cited JAAD Publication <sup>b</sup>	Year Published	JAAD H-index <sup>b</sup>
23	Thaci D (M)	925	74	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial	2015	10
24	Silverberg JI (M)	840	71	Association of atopic dermatitis with being overweight and obese: A systematic review and metaanalysis	2015	16
25	Wu JJ (M)	782	76	The association of psoriasis with autoimmune diseases	2012	14
26	Strober B (M)	725	92	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics	2019	13
27	Marghoob AA (M)	697	38	Accuracy in melanoma detection: A 10-year multicenter survey	2012	14
28	Longo C (F)	646	39	Skin aging: In vivo microscopic assessment of epidermal and dermal changes by means of confocal microscopy	2013	14
29	Paul C (M)	644	38	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey	2014	9
30	Tyring S (M)	617	89	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study	2017	10
31	Tosti A (F)	607	38	Systematic review of nondermatophyte mold onychomycosis: Diagnosis, clinical types, epidemiology, and treatment	2012	12
32	Alam M (M)	598	55	Ultrasound tightening of facial and neck skin: A rater-blinded prospective cohort study	2010	13
33	Rosenbach M (M)	586	45	Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study	2012	14
34	Poulin Y (M)	518	40	Interleukin 17A: Toward a new understanding of psoriasis pathogenesis	2014	10
35	Grant-Kels JM (F)	512	103	AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: A report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery	2012	8
36	Arias-Santiago S (M)	502	104	Frontal fibrosing alopecia: A multicenter review of 355 patients	2014	9
37	Puig S (F)	491	41	Benefits of total body photography and digital dermatoscopy ("two-step method of digital follow-up") in the early diagnosis of melanoma in patients at high risk for melanoma	2012	13
38	Lallas A (M)	454	34	Classifying distinct basal cell carcinoma subtype by means of dermatoscopy and reflectance confocal microscopy	2014	11
39	Malvey J (M)	446	36	Benefits of total body photography and digital dermatoscopy ("two-step method of digital follow-up") in the early diagnosis of melanoma in patients at high risk for melanoma	2012	11
40	Kricorian G (M)	441	35	Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment	2014	10
41	Duffin KC (F)	414	34	Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis	2013	12
42	Puig L (M)	403	34	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey	2014	8
43	West D (M)	399	95	Ultrasound tightening of facial and neck skin: A rater-blinded prospective cohort study	2010	10
44	Goederham M (F)	398	53	Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)	2016	9
45	Vano-Galvan S (M)	390	45	Frontal fibrosing alopecia: A multicenter review of 355 patients	2014	10
46	Weinstock MA (M)	385	47	The burden of skin disease in the United States	2017	10
47	Bagel J (M)	356	37	From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies	2014	7
48	Yosipovitch G (M)	354	46	Ipilimumab in patients with cancer and the management of dermatologic adverse events	2014	10
49	Elston DM (M)	351	62	Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations	2011	9
50	Gu YH (F)	347	42	Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL	2012	6

<sup>a</sup>First, a list of 100 authors with the highest number of JAAD publications was generated; from this list, author ranking was determined by the number of citations from his/her JAAD publications  
<sup>b</sup>Obtained from citation report generated by WOS Core Collection basic search of the author category, filtering for JAAD publications from January 2010 to September 2020

36 percent of first authors in our analysis (most cited JAAD articles from 2010 to 2020).<sup>3</sup> Furthermore, in our study, 48 percent of corresponding authors (for the 50 most cited JAAD articles) were women, while Maymone et al. reported 11 percent of senior authors were women (50 most cited dermatology articles).<sup>3</sup> However, this comparison should be interpreted with caution, as senior author and corresponding author are not always synonymous. Lastly, our analysis showed a much higher percentage of top cited women authors (28 percent) compared to the study by Maymone et al. (6 percent).<sup>3</sup>

Despite the increased representation of women authors within JAAD over the last decade, women continue to be underrepresented in academic dermatology. For example, only 24 percent of dermatology department chairs and 31 percent of full dermatology professor positions were held by women in 2015.<sup>26</sup> Further studies are needed to investigate why women remain underrepresented in academic dermatology.

We would like to address an important limitation in our analysis of the 50 most cited JAAD authors. By selecting the 50 cited authors from the list of 100 authors with the most JAAD publications, we may have missed authors with a fewer number of high impact JAAD publications. As such, our top cited author ranking reflects both productivity and publication impact.

Other study limitations include use of a single citation index and determination of gender based on a Google search. Furthermore, our analysis only captured publications and authors included in the “dermatology field” of WOS. It is also important to consider that citation rate provides only a snapshot into publication impact. Consequently, other landmark articles with a high readership and large influence on dermatology practice may have been missed.

## CONCLUSION

We would like to acknowledge the contribution of the JAAD, and its dedicated authors, within the last decade. Psoriasis and skin cancer continue to be the topics of highly cited dermatology publications. This is likely attributed to their significant disease burden and recent treatment and diagnostic developments. Guidelines of care provide the dermatological community with critical appraisals of the recent literature and will likely continue to increase in popularity. Future research is needed to investigate reasons for underrepresentation of women in academic dermatology. ■

*Amylee Martin, BS, School of Medicine, University of California, Riverside, CA.*

*Akshitha Thatiparthi, BS, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA.*  
*Jeffrey Liu, BS, Keck School of Medicine, University of Southern California, Los Angeles.*

*Jashin J Wu, MD, Research and Education Foundation, Irvine, CA.*

*Dr. Wu is or has been an investigator, consultant, or speaker for AbbVie, Ammiral, Amgen, Arcutis, Aristeia Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dr. Reddy's Laboratories, Eli Lilly, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Regeneron, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, Valeant Pharmaceuticals North America LLC, and Zerigo Health.*

1. About the Academy. American Academy of Dermatology Website. <https://www.aad.org/about-aad>. Accessed November 18, 2020.
2. Aims and Scope. Journal of the American Academy of Dermatology Website. <https://www.jaad.org/content/aims>. Accessed November 18, 2020.
3. Maymone MBC, Laughter M, Vashi NA, et al. The most cited articles and authors in dermatology: A bibliometric analysis of 1974-2019. *J Am Acad Dermatol*. 2020;83(1):201-205. doi:10.1016/j.jaad.2019.06.1308
4. List of Issues: Journal of the American Academy of Dermatology. [https://www.jaad.org/issues#decade=loi\\_decade\\_197](https://www.jaad.org/issues#decade=loi_decade_197). Accessed November 18, 2020.
5. Web of Science Core Collection - Web of Science platform. Clarivate Website. <https://clarivate.com/webofscience-platform/wosc>. Accessed September 28, 2020.
6. Liu J, Thatiparthi A, Martin A, Egeberg A, Wu JJ. Prevalence of Psoriasis Among Adults in the U.S. 2009-2010 and 2013-2014 National Health and Nutrition Examination Surveys. *J Am Acad Dermatol*. October 2020. doi:10.1016/j.jaad.2020.10.035
7. Rogers HW, Weinstein MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinoma) in the us population, 2012. *JAMA Dermatology*. 2015;151(10):1081-1086. doi:10.1001/jamadermatol.2015.1187
8. Wilmer EN, Gustafson CJ, Ahn CS, et al. Most common dermatologic conditions encountered by dermatologists and nondermatologists. *Cutis*. 2014 Dec;94(6):285-92
9. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. *J Am Acad Dermatol*. 2017;76(3):377-390. doi:10.1016/j.jaad.2016.07.064
10. Komine M. Recent advances in psoriasis research; The clue to mysterious relation to gut microbiome. *Int J Mol Sci*. 2020;21(7). doi:10.3390/ijms21072582
11. Rønholt K, Iversen L. Old and new biological therapies for psoriasis. *Int J Mol Sci*. 2017;18(11). doi:10.3390/ijms18112297
12. Carrasosa JM, Del-Alcazar E. New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management. *Expert Rev Clin Immunol*. 2018;14(4):259-273. doi:10.1080/1744666X.2018.1454835
13. Rouse NC, Farhangian ME, Wehausen B, Feldman SR. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. *Expert Rev Pharmacoecon Outcomes Res*. 2015;15(6):877-884. doi:10.1586/14737167.2015.1102634
14. Skalko-Basnet N. Biologics: The role of delivery systems in improved therapy. *Biol Targets Ther*. 2014;8:107-114. doi:10.2147/BTT.338387
15. US Department of Health and Human Services. The Surgeon General's Call to Action to Prevent Skin Cancer. Washington (DC): Office of the Surgeon General (US); 2014.
16. Guy GP Jr, Thomas CC, Thompson T, et al.; Centers for Disease Control and Prevention (CDC). Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030. *MMWR Morb Mortal Wkly Rep*. 2015 Jun 5;64(21):591-6.
17. Zalaudek I, Kersch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: A review of vascular structures seen with dermoscopy: Part II. Nonmelanocytic skin tumors. *J Am Acad Dermatol*. 2010;63(3):377-386. doi:10.1016/j.jaad.2009.11.697
18. Rajadhyaksha M, Marghoob A, Rossi A, Halpern AC, Nehal KS. Reflectance confocal microscopy of skin in vivo: From bench to bedside. *Lasers Surg Med*. 2017;49(1):7-19. doi:10.1002/lsm.22600
19. Fried L, Ian A, Bajaj S, et al. Technological advances for the detection of melanoma: Advances in molecular techniques. *J Am Acad Dermatol*. 2020;83(4):996-1004. doi:10.1016/j.jaad.2020.03.122
20. Domingues B, Lopes J, Soares P, Popolo H. Melanoma treatment in review. *ImmunoTargets Ther*. 2018;Volume 7:35-49. doi:10.2147/itt.s134842
21. FDA approves Libtayo, first drug specifically for advanced cutaneous squamous cell carcinoma. Healio Website. <https://www.healio.com/news/hematology-oncology/20180928/fda-approves-libtayo-first-drug-specifically-for-advanced-cutaneous-squamous-cell-carcinoma>. Accessed November 25, 2020.
22. FDA approves pembrolizumab for cutaneous squamous cell carcinoma. U.S. Food & Drug Administration Website. <https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-cutaneous-squamous-cell-carcinoma>. Accessed November 25, 2020.
23. Fellingner C. Vismodegib (erivedge) for advanced Basal cell carcinoma. *P T*. 2012 Dec;37(12):670-82.
24. Sonidegib Approved for Advanced Basal Cell Carcinoma. National Cancer Institute Website. <https://www.cancer.gov/news-events/cancer-currents-blog/2015/sonidegib-bcc>. Accessed November 25, 2020.
25. Drake LA. American Academy of Dermatology Guidelines of Care. *Arch Dermatol*. 1997;133(11):1369. doi:10.1001/archderm.1997.03890470043007
26. Larson AR, Poorman JA, Silver JK. Representation of Women among Physician Authors of Perspective-Type Articles in High-Impact Dermatology Journals. *JAMA Dermatology*. 2019;155(3):386-388. doi:10.1001/jamadermatol.2018.5517